Pfizer에 대한 매도 수량은 투자자에게 Pfizer의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Pfizer (NYSE:PFE) 주식, 공매도 수량 보고

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Earnings

News

Pre-Market Outlook

Markets

GOOG

GOOGL

오늘 화요일 미국 주식 선물은 혼조세를 보이고 있으며, 오늘 투자자들의 주목을 받을 수 있는 몇 가지 주식은 다음과 같다: 1. 월스트리트에서는 화이자(NYSE:PFE)가 개장 전 분기 실적으로 주당 62센트, 매출을 149억 5천만 달러를 발표할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면, 화이자의 주식은 시간외 거래에서 0.3% 상승하여 28.95달러로 거래되었다.

화요일 주목해야 할 주식: 화이자, 알파벳, 포드 자동차, 맥도날드 및 필립스 66

Equities

화이자(NYSE:PFE)의 CEO인 알버트 불라(Albert Bourla)가 주가 회복과 전략적 초점 재조정을 요구하는 압박이 커지는 가운데 행동주의 투자자 스타보드 밸류(Starboard Value)와 만날 예정이다. 이 만남은 스타보드가 화이자에 약 10억 달러 규모의 지분을 확보하면서 이루어지는 것으로, 이는 화이자의 1,650억 달러 시장 가치의 약 0.6%에 해당한다.

화이자 CEO 알버트 불라, 행동주의 투자자 스타보드 밸류와 만날 예정: 보도

Global

행동주의 투자자인 스타보드 밸류(Starboard Value)가 화이자(NYSE:PFE)에 약 10억 달러를 투자했다. 이 전략적 움직임은 이 제약 대기업이 COVID-19 백신과 치료제에 대한 수요 감소로 어려움을 겪고 있는 시점에서 이루어졌다.

투자자 스타보드 밸류가 코로나19 치료제 수요 감소로 고전하는 화이자에 $10억 투자: 보도

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFIZER ORD

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) short percent of float has risen 5.04% since its last report. The company recently reported that it has 70.94 million shares sold short, which is 1.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Pfizer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730814324_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pfizer has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pfizer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Pfizer's peer group average for short interest as a percentage of float is 4.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Pfizer's Recent Short Interest

Contracts

ITRM

Iterum Therapeutics Notified Pfizer, Electing To Defer Milestone Payment For 2 Years For ORLYNVAH, Or Until Oct 25, 2026

On Thursday, ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) announced its plans to terminate the Phase 2 trial of masofaniten combined with enzalutamide versus enzalutamide single agent in patients with metastatic castration-resistant prostate cancer (mCRPC) naïve to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41669391/essa-pharma-announces-termination-of-phase-2-study-evaluating-masofaniten-combined-with-enzalutami" rel="noreferrer noopener">second-generation antiandrogens</a>.
This decision was based on a protocol-specified interim review of the safety, PK, and efficacy data, which showed a much higher rate of PSA90 response in patients treated with Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xtandi (enzalutamide) monotherapy (which is the standard of care for this patient population) than expected based on historical data.
In addition, there was no clear efficacy benefit seen with the combination of masofaniten plus enzalutamide compared to enzalutamide single agent.
A futility analysis determined a low likelihood of meeting the prespecified primary endpoint of the study.
The combination of masofaniten plus enzalutamide was well-tolerated with no new safety signals and a safety profile similar to that seen in Phase 1 studies.
&#8220;We made the difficult decision to terminate this Phase 2 study following the interim analysis because we concluded that the emerging efficacy profile of masofaniten combined with enzalutamide would not likely meet the primary endpoint of the study, nor our internal requirements for a prostate cancer therapy candidate,&#8221; said&nbsp;David Parkinson, President, and CEO.
As part of the effort to focus its resources, ESSA is also planning to terminate the other remaining company-sponsored and investigator-sponsored clinical studies evaluating masofaniten either as a monotherapy or in combination <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40862721/essa-pharma-presents-updated-phase-12-masofaniten-epi-7386-clinical-data-at-the-2024-esmo-congress" rel="noreferrer noopener">with other agents</a>.
As of&nbsp;September 30, 2024, the company had available cash reserves and short-term investments of&nbsp;$126.8 million&nbsp;and net working capital of&nbsp;$124.3 million.
In September, ESSA Pharma announced the presentation of updated dose escalation data from its Phase 1/2 study of masofaniten (formerly EPI-7386) in combination with enzalutamide at the 2024 European Society for Medical Oncology (ESMO) Congress.
Across all dose cohorts, 88% of patients (14 of 16) achieved PSA50, 88% of patients (14 of 16) achieved PSA90, 69% of patients (11 of 16) achieved PSA90 in less than 90 days, and 63% of patients (10 of 16) achieved PSA &lt;0.2ng/mL.
Price Action: EPIX stock was down 69.80% at $1.57 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/11/41685490/nvidias-run-ai-acquisition-draws-european-regulatory-scrutiny-on-competition-concerns" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Run: ai Acquisition Draws European Regulatory Scrutiny On Competition Concerns</a></li>
</ul>

Biotech

Health Care

Movers

General

EPIX

Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy

<a href="https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/">https://www.statnews.com/2024/10/30/novo-nordisk-ozempic-wegovy-fda-available-or-in-shortage/</a>
All doses of Novo Nordisk&#39;s blockbuster diabetes and obesity treatments are <a href="https://dps.fda.gov/drugshortages/activeingredient/semaglutide-injection">listed as available</a> on the Food and Drug Administration&#39;s drug shortage list as of Wednesday, raising the possibility that the medications could soon be taken off the list entirely, a development that could affect compounding pharmacies and patients relying on compounded drugs.
Semaglutide, the scientific name for Novo&#39;s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times. With all doses now listed as available, the FDA may soon pull it off the list, depending on its conversations with Novo about whether the company can sufficiently meet demand going forward.
Over the past two years, patients seeking treatment have been turning to compounding pharmacies, which make cheaper copies of branded treatments and are legally allowed to do so only when the branded treatments are listed on the FDA&#39;s shortage list.&nbsp;

&nbsp;

AMGN

DRIO

Hims & Hers Health, Inc. Class A Common Stock

HIMS

RHHBY

TERN

VANI

VKTX

Reported Earlier, 'Novo Nordisk's Ozempic and Wegovy, long in shortage, are now listed as available by FDA; It remains unclear how the update could affect patients as well as compounders' - STAT News

Analyst Ratings

DELL

LDOS

CNBC Halftime Report Final Trades: Dell Technologies, Leidos, Pfizer, The Trade Desk

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Tuesday.
U.S. stocks settled mixed on Tuesday, with the Nasdaq Composite surging to a new record high during the session.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) reported better-than-expected results for its third quarter. McDonald&#8217;s Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) posted better-than-expected third-quarter earnings on Tuesday.
On the economic data front, the S&amp;P CoreLogic Case-Shiller home price index rose 5.2% year-over-year in August versus a 5.9% gain in July. U.S. wholesale inventories declined by 0.1% month-over-month to $905 billion in September compared to a revised 0.2% gain in the earlier month. The U.S. trade deficit increased to $108.2 billion in September from the $94.2 billion gap in the previous month.
Most sectors on the S&amp;P 500 closed on a negative note, with energy, consumer staples, and utilities stocks recording the biggest losses on Tuesday. However, information technology and communication services stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 155 points to 42,233.05 on Tuesday. The S&amp;P 500 rose 0.16% to 5,832.92, while the Nasdaq Composite climbed 0.78% to close at 18,712.75 during Tuesday's session.
Investors are awaiting earnings results from Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), and Starbucks Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 60.2, the index remained in the &#8220;Greed&#8221; zone on Tuesday, versus a prior reading of 60.9.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41599928/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-for-october">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio For October</a></li>
</ul>
Photo courtesy: Shutterstock

MSFT

SBUX

Nasdaq Hits Record High Ahead Of Big Tech Earnings: Fear Index Remains In 'Greed' Zone

Wall Street took a breather on Tuesday, with most major indices treading water, while tech stocks saw gains as investors braced for earnings <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41579487/amd-q3-earnings-preview-can-ai-server-gains-help-narrow-the-semiconductor-gap-with-">reports from mega-cap companies.</a>
The Nasdaq 100 rose 0.7%, buoyed by anticipation around upcoming earnings from Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) and Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), both set to report after market close.
Elsewhere, the S&amp;P 500 was largely unchanged, the Dow Jones dipped slightly, and small-cap stocks underperformed.
In economic news, U.S. job openings dropped by 418,000 to 7.443 million in September 2024 — marking the lowest level since January 2021 and falling short of the market's expectation of 7.99 million.
The Conference Board&#8217;s Consumer Confidence Index surged, posting its largest monthly gain since March 2021. This suggests that while labor demand may be slowing, consumer sentiment remains robust.
Treasury yields continued to climb during concerns over the U.S. budget deficit and political uncertainty ahead of next week's elections. The yield on the 10-year Treasury note hit 4.33%, the highest level since early July.
Notably, gold prices remained resilient, with the precious metal breaking above the all-time high of $2,770 per ounce as investors sought a hard asset amid fiscal concerns.
The crypto market also saw notable gains. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose nearly 4% to reach $72,700, nearing its record high of $73,697 set in March. Dogecoin (CRYPTO: DOGE) continued its momentum with a 10% rally on Tuesday, following an 11% surge on Monday.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,500.69</td>
<td>0.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,831.03</td>
<td>0.1 %</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,272.72</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,226.40</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102824&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.1% higher to $581.48.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;dipped 0.3% to $422.93.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.7% to $498.73.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% to $221.01.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up by 1.1%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.7%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks reacting to earnings reports included: 
<ul>
<li>McDonalds Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), down 0.4%, </li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), down 1.7%, </li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>), down over 4%, </li>
<li>Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>), down 1%, </li>
<li>Enterprise Product Partner L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) down 0.3%, </li>
<li>Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) up 3.5%, </li>
<li>D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>), down 8.6%, </li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), down 3.9%, </li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>), down 1.5%, </li>
<li>Corning Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>), up 7.8%, </li>
<li>Ford Motor Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/F#NASDAQ">F</a>), down 8%, </li>
<li>SoFi Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NYSE">SOFI</a>), down 6.3%, </li>
<li>Incyte Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NASDAQ">SWK</a>), up 9.4%</li>
</ul>
Among large-cap companies slated to report earnings after the close are Alphabet, Advanced Micro Devices, Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Stryker Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), Chubb Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>), Mondelez International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>), Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) and Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>).
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41599323/6-economic-frights-that-could-haunt-markets-this-halloween-a-tipping-point-for-risk">6 Economic Frights That Could Haunt Markets This Halloween: &#8216;A Tipping Point For Risk Appetite,&#8217; Analysts Warn</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

MDLZ

MSCI

PYPL

SOFI

Tech Stocks Rise Ahead Of Key Earnings, Gold Smashes Records, Bitcoin Nears All-Time Highs: What's Driving Markets Tuesday?

Pfizer CEO Says Will Do 'Whatever It Takes' To Grow Earnings

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Tuesday.
The Dow traded down 0.07% to 42,357.35 while the NASDAQ rose 0.74% to 18,704.19. The S&amp;P 500 also rose, gaining, 0.34% to 5,843.35.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41598310/jim-cramer-avoid-this-consumer-cyclical-stock-buy-lam-research">Jim Cramer: &#8216;Avoid&#8217; This Consumer Cyclical Stock, Buy Lam Research</a>
Leading and Lagging Sectors Communication services shares rose by 1.2% on Tuesday.
In trading on Tuesday, utilities shares fell by 1.6%.
Top Headline
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) reported better-than-expected results for its third quarter.
The company posted third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ago, beating the consensus of 62 per share. The U.S. drugmaker reported sales of $17.70 billion, up 31% year-over-year (up 32% operationally), beating the consensus of $14.95 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares shot up 161% to $0.4352 after the company announced it will merge with Crescent Biopharma and secured $200 in funding to advance its oncology pipeline.</li>
<li>Shares of BIO-key International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) got a boost, surging 95% to $1.3100 after the company announced it received a $910K order from a long-time financial services customer to upgrade its biometric customer identification technology.</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares were also up, gaining 47% to $82.32 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) shares dropped 66% to $0.4235 after the company priced an $11.1 million public offering at $1.26 per unit.</li>
<li>Shares of TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) were down 30% to $87.89 after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue guidance with its midpoint below estimates.</li>
<li>Janus International Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBI#NYSE">JBI</a>) was down, falling 28% to $7.45 after the company reported worse-than-expected third-quarter financial results and cut its FY24 sales guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded up 0.2% to $67.51 while gold traded up 1% at $2,782.00.
Silver traded up 1.9% to $34.630 on Tuesday, while copper rose 0.1% to $4.3650.
Euro zone
European shares were lower today. The eurozone's STOXX 600 slipped 0.37%, Germany's DAX fell 0.18% and France's CAC 40 slipped 0.29%. Spain's IBEX 35 Index fell 0.74%, while London's FTSE 100 fell 0.52%.
Retail sales in Spain rose by 4.1% year-over-year in September, while retail sales volumes in the UK fell by 6% in October following a 4% increase in September.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.77%, Hong Kong's Hang Seng Index gaining 0.49%, China's Shanghai Composite Index falling 1.08% and India's BSE Sensex surging 0.45%.
Hong Kong&#8217;s trade deficit shrank to $53.2 billion in September from $64.6 billion in the year-ago month.
Economics
<ul>
<li>The number of job openings declined by 418,000 to 7.443 million in September versus a revised 7.861 million in the previous month and below market estimates of 7.99 million.</li>
<li>The FHFA house price index rose 0.3% in August, above market estimates of a 0.2% rise.</li>
<li>The S&amp;P CoreLogic Case-Shiller home price index rose 5.2% year-over-year in August versus a 5.9% gain in July.</li>
<li>U.S. wholesale inventories declined by 0.1% month-over-month to $905 billion in September compared to revised 0.2% gain in the earlier month.</li>
<li>The U.S. trade deficit increased to $108.2 billion in September from the $94.2 billion gap in the previous month.</li>
<li>The Dallas Fed general business activity index for Texas&#8217; service sector climbed to 2 in October compared to a reading of -2.6 in the prior month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41598309/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Eurozone

Intraday Update

BKYI

EFSH

GLYC

TMDX

Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views

Pfizer CEO Bourla Says Meeting With Starboard Was Constructive And Cordial; Some Seagen Pipeline Assets Have Potential To Be "Megablockbusters"

On Tuesday,&nbsp;Pfizer Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) reported third-quarter adjusted EPS of $1.06, a turnaround from loss of 17 cents a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.62</a>.
The U.S. drugmaker reported sales of $17.70 billion, up 31% year-over-year (up 32% operationally), beating the&nbsp;consensus of $14.95 billion.
The increase was primarily led by growth contributions from Paxlovid and several acquired products, key in-line products, and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41594926/pfizer-reports-strong-third-quarter-2024-results-and-raises-2024-guidance" rel="noreferrer noopener">recent commercial launches</a>.
Excluding contributions from Paxlovid and Comirnaty (COVID-19 products), revenues totaled $13.6 billion, an increase of $1.7 billion, or 14%, operationally.
Third-quarter 2024 Paxlovid revenues of $2.7 billion increased $2.5 billion operationally compared with the prior-year quarter, primarily due to strong demand, particularly in the U.S., driven by higher utilization during a recent global COVID-19 wave; the one-time contractual delivery of one million treatment courses to the U.S. Strategic National Stockpile in the third quarter of 2024.
Comirnaty revenues of $1.4 billion increased by 9%, driven primarily by the timing of stocking due to earlier approval of the new variant vaccine in the U.S. in 2024 compared to 2023, partially offset by lower contractual deliveries and demand in international markets.
Vyndaqel family drugs generated&nbsp;<a target="_blank" href="https://s28.q4cdn.com/781576035/files/doc_financials/2024/q3/Q3-2024-PFE-Earnings-Release-Final.pdf" rel="noreferrer noopener">sales</a> of $1.45 billion, up 62%. Eliquis, a blood thinner drug, generated sales of $1.62 billion, up 8%.
Global revenues of $854 million came from legacy Seagen, acquired in December 2023.
Guidance:&nbsp;Pfizer updates its 2024 revenue forecast to $61 billion-$64 billion compared to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/40037079/pfizer-marks-first-revenue-growth-since-covid-revenue-peak-in-2022-lifts-annual-guidance" rel="noreferrer noopener">prior guidance of $59.5 billion-$62.5 billion</a> and consensus of $61.16 billion.
The company's updated guidance includes approximately $10 billion (vs. $8.5 billion expected earlier) in anticipated revenues for Comirnaty&nbsp;and Paxlovid, approximately $5 billion and $5.5 billion ($3.5 billion expected earlier), respectively.
Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer expects full-year 2024 operational revenue growth of 9% to 11% compared to 2023 revenue. This growth guidance considers the reduction of sales associated with the previously announced global withdrawal of Oxbryta.
Pfizer Expects 2024 adjusted EPS of $2.75-$2.95 compared to prior guidance of $2.45-$2.65 and consensus of $2.65.
Price Action:&nbsp;At the last check on Tuesday, PFE stock was up 2.04% at $29.45 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41583831/surgical-robotics-provider-procept-biorobotics-q3-earnings-beats-street-view-analys" target="_blank" rel="noreferrer noopener">Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential</a></li>
</ul>
Photo via Company

Large Cap

Guidance

Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products

U.S. stocks could see a weak opening on Tuesday after the <a href="https://www.benzinga.com/markets/equities/24/10/41556896/investors-cautious-with-election-ahead-treasury-yields-surge-further-tesla-surprises-this-week-i">averages registered a mixed last week</a>. While the S&amp;P 500 and Dow Jones snapped their six-week winning streak, the Nasdaq Composite chalked its seventh straight week of gains.
Earning news flow will continue to pick up momentum in the coming days, with five of the seven &#8220;Magnificent 7&#8221; companies all set to post their earnings this week – this includes Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.05%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.04%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.10%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.39%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.07% to $580.44 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged up by 0.03% to $495.54, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
The Dow Jones ended its five-day losing streak on Monday, closing the day up by 0.65%. Nasdaq Composite continued to surge in the run-up to five of the seven earnings from "Magnificent 7" stocks this week.
Crude oil prices recovered slightly after tumbling over the weekend due to simmering tensions in the Middle East and Israel's missile strikes in Iran.
Treasury yields continued to rise, signaling concerns that regardless of who wins the elections, the next administration might struggle with fiscal discipline. This sentiment was further exacerbated by the International Monetary Fund's warnings on the long-term trajectory <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41495286/deficit-strain-in-washington-will-get-worse-imf-warns-national-debt-projections-rev" target="_blank" rel="noreferrer noopener">of the U.S. national debt</a>.
On the economic data front, the Federal Reserve Bank of Dallas&#8217; general business activity index for manufacturing in Texas rose to -3 in October compared to a reading of -9 in September.
All the three major indices surged on Monday.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.26%</td>
<td>18,567.19</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.27%</td>
<td>5,823.52</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.65%</td>
<td>42,387.57</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.63%</td>
<td>2,244.07</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Sam Stovall, chief investment strategist at CFRA Research, <a href="https://cnbc.com/video/2024/10/28/would-not-surprise-me-if-earnings-results-exceed-estimates-says-cfras-sam-stovall.html">told</a> CNBC in an interview that the overall earnings season could exceed expectations.
"I obviously would not be surprised if this ends up being 60th out of the last 62 quarters in which the actual results exceed end-of-quarter estimates," Stovall said.
On a possible post-election relief rally, Stovall said, "Historically, the market does breathe a sigh of relief."
Explaining the ongoing bull market, WisdomTree and Wharton School economist&nbsp;Jeremy Siegel pointed to the rally in the tech sector, with Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) leading the charge.
"The tech sector remains the biggest mover, led by companies like Tesla, which continues to defy gravity thanks to its strong positioning in EVs and autonomous driving technology."
Talking about a possible re-election of former President Donald Trump, Siegel said, "A Republican sweep—where the GOP gains control of both the Senate and House—could lead, at least temporarily, to an increased fear of higher deficits, causing bond yields to move up significantly."
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
Tuesday's economic calendar is fairly light.
<ul>
<li>Retail (ex-auto) and wholesale inventories data will be released at 8:30 a.m. ET.</li>
<li>S&amp;P Case-Shiller home price index will be released at 9 a.m. ET.</li>
<li>Consumer confidence index will be released at 10 a.m. ET.</li>
<li>Job openings data will be released at 10 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares fell by nearly 5.5% in premarket trading after the automaker <a href="https://www.benzinga.com/news/earnings/24/10/41587260/ford-q3-earnings-revenue-beat-eps-beat-ev-sales-down-33-updated-fy-outlook-shares-slide">cut revenue and profit guidance</a>.</li>
<li>McDonald's Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) shares fell nearly 2% in premarket trading after the fast food giant reported a higher-than-expected fall in global sales.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares soared nearly 13% following Trump's rally at Manhattan's Madison Square Garden over the weekend.</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) priced its offering at $143 per share, with 112.5 million shares up for purchase.</li>
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) shares surged 3.4% after Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) crossed the $71,000 mark.</li>
<li>Earnings from Alphabet Inc., Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) will be on investors' radar on Tuesday.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures edged up in the early New York session, rising by 1% after tumbling over 6% during the weekend.
The 10-year Treasury note yield surged to 4.292%.
Major Asian markets ended mixed on Tuesday, while European stocks showed strength in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41591063/apple-will-be-the-first-to-hit-4-trillion-market-cap-milestone-says-dan-ives-as-hundreds-of-apps">Apple &#8216;Will Be The First To Hit&#8217; $4 Trillion Market Cap Milestone, Says Dan Ives As Hundreds Of Apps Will Be Built On AI Feature</a></li>
</ul>
Photo courtesy: Wikimedia

Futures

Previews

Federal Reserve

AAPL

AMZN

COIN

TSLA

US Stocks Likely To Open Weaker As Investors Eye Alphabet, AMD And Pfizer Earnings: Expert Says Won't Be 'Surprised' If Earnings Exceed Wall Street Expectations

Pfizer shares are trading higher after the company reported Q3 adjusted EPS and sales that beat analyst estimates and raised its 2024 guidance.

Pfizer Expects 2024 Sales Of $61B-$64B Compared To Prior Guidance Of $59.5B-$62.5B And Consensus Of $61.156B

The company's updated guidance for revenue includes approximately $10.5 billion in anticipated revenues for Comirnaty and Paxlovid, approximately $5 billion and $5.5 billion, respectively. Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer continues to expect full-year 2024 operational revenue growth of 9% to 11% compared to 2023 revenues; and this growth guidance takes into consideration the reduction of sales associated with the previously announced global withdrawal of Oxbryta.&nbsp;

Pfizer Expects 2024 Adjusted EPS Of $2.75-$2.95 Compared To Prior Guidance Of $2.45-$2.65 And Consensus Of $2.65

Pfizer Q3 2024 Adj. EPS $1.06 Beats $0.62 Estimate, Sales $17.702B Beat $14.954B Estimate

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Monday.
U.S. stocks settled higher on Monday, with the Dow Jones index surging more than 250 points ahead of earnings from megacap technology companies.
Both the Dow Jones and S&amp;P 500 ended a six-week winning streak, falling around 1% and 2.7%, respectively. The Nasdaq recorded gains for the seventh straight week, gaining nearly 0.2% last week.
Shares of Koninklijke Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) tumbled around 16% on Monday after the company reported weak third-quarter earnings results.
On the economic data front, the Federal Reserve Bank of Dallas' general business activity index for manufacturing in Texas rose to -3 in October compared to a reading of -9 in September.
Most sectors on the S&amp;P 500 closed on a positive note, with financials, materials, and utilities stocks recording the biggest gains on Monday. However, information technology and energy stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 273 points to 42,387.57 on Monday. The S&amp;P 500 rose 0.27% to 5,823.52, while the Nasdaq Composite climbed 0.26% to close at 18,567.19 during Monday's session.
Investors are awaiting earnings results from Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), and McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 61.7, the index remained in the &#8220;Greed&#8221; zone on Monday, versus a prior reading of 60.8.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41574887/top-3-industrials-care-stocks-that-plunge-this-month">Top 3 Industrials Care Stocks That Plunge This Month</a></li>
</ul>
Photo courtesy: Shutterstock

Dow Surges Over 250 Points Ahead Of Alphabet, Pfizer Earnings: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone

With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) to report quarterly earnings at 62 cents per share on revenue of $14.95 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Pfizer shares gained 0.3% to $28.95 in after-hours trading.</li>
<li>Analysts are expecting Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) to post quarterly earnings at $1.66 per share on revenue of $34.46 billion. The company will release earnings before the markets open. Phillips 66 shares rose 0.3% to $129.32 in after-hours trading.</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) posted better-than-expected earnings and sales results for the third quarter. However, the company said it sees full-year adjusted EBITDA of about $10 billion. Ford shares declined 6% to $10.69 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Before the markets open, McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) is projected to report quarterly earnings at $3.2 per share on revenue of $6.82 billion. McDonald&#8217;s shares gained 0.1% to $297.20 in after-hours trading.</li>
<li>Analysts expect Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) to report quarterly earnings at $1.84 per share on revenue of $86.31 billion after the closing bell. Alphabet shares gained 0.5% to $167.50 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41574887/top-3-industrials-care-stocks-that-plunge-this-month">Top 3 Industrials Care Stocks That Plunge This Month</a></li>
</ul>
Photo courtesy: Shutterstock

Pfizer, Alphabet And 3 Stocks To Watch Heading Into Tuesday

The global <a href="https://www.benzinga.com/markets/psychedelics">psychedelic drugs market</a> is set for rapid expansion, with projections forecasting growth from $4.88 billion in 2023 to $10.2 billion by 2028, <a href="https://www.einpresswire.com/article/754811757/global-psychedelic-drugs-market-outlook-2024-2033-growth-drivers-share-and-trends">according</a> to The Business Research Company. With a compound annual growth rate of 16.1%, this rise is largely driven by increased awareness of mental health needs, progressive regulatory shifts and the medical community's growing acceptance of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelics for therapeutic applications</a>.
<h3 class="wp-block-heading">Key Market Drivers: Mental Health Awareness And Regulatory Changes</h3>
The surge in mental health disorders, including <a href="https://www.benzinga.com/topic/treatment-resistant-depression">treatment-resistant depression</a> and <a href="https://www.benzinga.com/topic/ptsd">PTSD</a>, is fueling demand for alternative treatments like psychedelics. "Psychedelic drugs are utilized for treating depression and PTSD, contributing to a decrease in mental health issues," notes The Business Research Company. Psychedelics such as <a href="https://www.benzinga.com/topic/lsd">LSD</a>, <a href="https://www.benzinga.com/topic/ketamine">ketamine</a>, and newer innovations like depression-targeting nasal sprays are becoming prominent options for patients and providers alike.
<h3 class="wp-block-heading">Trends Shaping The Psychedelic Drugs Market</h3>
Key trends include a focus on public education, regulatory adaptation, and diversification of compounds. Companies such as Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Mydecine Innovations Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MYCOF#OTC">MYCOF</a>) are actively advancing in this sector to develop treatments that cater to evolving patient needs. North America currently leads the market, with Asia-Pacific expected to see the fastest growth through 2033 due to increasing <a href="https://www.benzinga.com/markets/cannabis/23/12/36107955/japan-approves-marijuana-derived-medicines-adopt-7-year-prison-sentences-for-recreational-use">policy changes</a> and investment in mental health infrastructure.
<h3 class="wp-block-heading">Market Segmentation: Psychedelic Compounds And Indications</h3>
The market includes various types of psychedelics categorized by drug (LSD, ketamine, GHB), indication (depression, PTSD) and origin (natural or synthetic). Applications range from treatment-resistant depression to panic disorders, with distribution spanning hospitals, retail and online pharmacies.
<h3 class="wp-block-heading">Outlook And Opportunities For Psychedelic Drug Developers</h3>
As research continues to support psychedelics&#8217; benefits in mental health treatment, companies are poised to capitalize on both emerging treatment areas and regional growth opportunities. With major pharmaceutical players investing in these compounds, the market is expected to become increasingly competitive and patient-focused, highlighting a promising outlook for psychedelic treatments.
Cover image made with AI

Cannabis

Psychedelics

MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC.

MYCOF

Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises

Google To Launch New "Sexual Health & Wellness" Policy On November 11, Permitting Promotion Of Personal Lubricants And Prescription Drugs In Select Countries

In a report released today, Carter Gould from Barclays maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $32.00. T...

Barclays Sticks to Its Hold Rating for Pfizer (PFE)

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Pfizer (PFE – Research Report) today. The company's shares closed last Fri...

Pfizer (PFE) Gets a Buy from Truist Financial

Evercore ISI analyst Umer Raffat maintained a Buy rating on Pfizer (PFE – Research Report) today. The company's shares closed last Friday at $28.09...

Evercore ISI Reaffirms Their Buy Rating on Pfizer (PFE)

Shares of BioNTech ($BNTX) gained in pre-market trading after the company reported better-than-expected Q3 earnings. The biotech company's earnings...

BNTX Earnings: BioNTech Reports Better-than-Expected Q3 Earnings, Lowers Revenue Outlook

A bit of earnings and election jitters roiled the market last week reordering  the leaderboard in biopharma stocks.

Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required

In times of market uncertainties, high-dividend yield stocks are ideal investment choices for their qualities like stable passive income, protection against inflation, and price appreciation. Thus, investors could consider fundamentally sound, high dividend yield stocks Verizon Communications (VZ), Pfizer (PFE), and Enterprise Products Partners (EPD) for steady passive income. Read more... High-dividend yield stocks allure investors with attractive yield levels, regular income streams, and growth potential in the long run. These stocks also have the potential to optimize investment portfolios against economic volatility and offer wide long-term growth prospects.
Against this backdrop, it could be wise to invest in fundamentally strong high dividend yield stocks Verizon Communications Inc. (<a href="https://stocknews.com/stock/VZ/">VZ</a>), Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), and Enterprise Products Partners L.P. (<a href="https://stocknews.com/stock/EPD/">EPD</a>) could be ideal buys for steady passive income.
The U.S. economy shows mixed signals, urging investors to seek stable investment alternatives. Amid this, high dividend yield stocks stand out as they offer a combination of reliable income and gradual capital appreciation, suitable for investors seeking passive income and protection from economic volatility.
During the third quarter, the <a href="https://www.bea.gov/news/2024/gross-domestic-product-third-quarter-2024-advance-estimate">U.S. economy's real gross domestic product</a> increased at an annual rate of 2.8%, according to the "advance" estimate of the U.S. Bureau of Economic Analysis. The growth in the current quarter was propelled by solid consumer spending and favorable government spending. The growth was lower than the second quarter real GDP of 3.0%.
The GDP growth was also below the 3.1% estimate of economists. Further, continuous import growth, outpacing export growth, contributes to the economic slowdown. <a href="https://www.conference-board.org/brief/global-economy/gdp-q3-2024#:~:text=Real%20GDP%20growth%20remained%20healthy,anticipated%20roughly%203%20percent%20growth.">For the fourth quarter</a>, the real GDP growth is also expected to be slow as hurricane effects and inventory destocking limited the expansion. Also, speculation of another rate cut and inflation continue to be a concern.
Therefore, against the economic uncertainties, high-dividend yield stocks pose a bright investment prospect for investors. The benefit of dividends makes a stock more appealing to investors, providing potential for regular dividend earnings and capital appreciation. Also, investing in high dividend-yield stocks ensures that the company is performing well financially.
Given the economic trends, investing in high dividend yield stocks with dividend yield above 5%, such as VZ, PFE, and EPD, could be wise for future gains.
Verizon Communications Inc. (<a href="https://stocknews.com/stock/VZ/">VZ</a>)
VZ offers international communications, technology, information, and entertainment products and services to consumers, businesses, and governmental entities. The company operates through Verizon Consumer Group (Consumer) and Verizon Business Group (Business) segments.
On October 24, VZ launched its new app, Verizon Family, a digital service that helps families stay connected and safe. The app helps in monitoring a family's location, is built with new features like Safe Walk with an SOS button to contact a family member in an emergency, and even keeps an eye on children's Verizon calls and texts.
The new Verizon family app enhances family safety and is currently available for free to VZ customers on any postpaid plan via the App Store and Google Play.
On October 23, Verizon Frontline launched two new deployable asset prototypes designed to support the mission-critical communications needs of first responders during public safety operations. The two new Verizon Frontline prototype assets are capable of establishing their own off-grid network, allowing first responders to communicate with each other in challenging situations.
Also, on September 4, VZ increased its quarterly <a href="https://www.investopedia.com/terms/d/dividend.asp">dividend</a> by 1.25 cents to $0.6775 per share, paid to its shareholders on November 1, 2024.
VZ has raised its annual dividend for 20 consecutive years. It pays an annual dividend of $2.71, which translates to a yield of 6.55% at the current share price. Its four-year average dividend yield is 5.87%. Moreover, the company's dividend payouts have increased at an impressive CAGR of 1.9% over the past three years.
For the third quarter that ended September 30, 2024, VZ reported total operating revenues of $33.33 billion, and its operating income came in at $5.93 billion for the same period. The company's net income and EPS totaled $3.41 billion and $0.78 for the quarter.
Furthermore, the company's cash and cash equivalents stood at $4.99 billion as of September 30, 2024, compared to $2.06 billion as of December 31, 2023.
Analysts expect VZ's revenue and EPS for the fourth quarter (ending December 2024) to grow 0.9% and 2.9% year-over-year to $35.45 billion and $1.11, respectively. Also, the company topped the consensus EPS estimates in three of the four trailing quarters.
Shares of VZ have surged 5.5% over the past six months and 16.8% over the past year to close the last trading session at $41.36.
VZ's solid fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
VZ has a B grade for Growth and Stability. It is ranked #4 out of 20 stocks in the C-rated <a href="https://stocknews.com/category/telecom-domestic/">Telecom - Domestic</a> industry.
In addition to the POWR Ratings we've stated above, we also have VZ ratings for Quality, Momentum, Value, and Sentiment. Get all VZ ratings <a href="https://stocknews.com/stock/VZ/">here</a>.
Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products internationally. The company provides medicines and vaccines in various therapeutic areas, like cardiovascular metabolic, migraine, and women's health, under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands.
On October 22, PFE announced that the U.S. FDA approved its ABRYSVO&#xAE; (Respiratory Syncytial Virus Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine for preventing lower respiratory tract disease (LRTD) caused by RSV in individuals between 18 and 59 years of age.
The approval is based on data from the pivotal Phase 3 trial. ABRYSVO offers the broadest indication of the RSV vaccine in adults. It is the first and only respiratory syncytial virus vaccine for adults younger than 50. The indication has been expanded to benefit older adults and pregnant women.
On October 11, PFE received FDA approval for HYMPAVZI&#x2122; (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A.
The approval of HYMPAVZI marked a significant advancement for people living with hemophilia A or B without inhibitors for bleed prevention.
On October 9, PFR's Board of Directors declared a $0.42 fourth-quarter 2024 dividend on its common stock, payable on December 2, 2024, to holders of record at the close of business on November 8, 2024.
PFE pays an annual dividend of $1.68, which translates to a yield of 5.98% at the current share price. Its four-year average dividend yield is 4.24%. Moreover, the company's dividend payouts have increased at a CAGR of 4.4% over the past five years. PFE has raised its dividend for 13 consecutive years.
In the third quarter that ended September 29, 2024, PFE's total revenues increased 31.2% year-over-year to $17.70 billion, of which its product revenues grew 33.1% from the year-ago value to $15.42 billion. The company's adjusted net income and adjusted EPS came in at $6.05 billion and $1.06 for the quarter, respectively.
Buoyed by strong financial performance, the company raised its full-year 2024 revenue guidance to a range of $61 billion to $64 billion from the prior range of $59.50 to $62.50 billion. It also raised its adjusted EPS guidance to a $2.75 to $2.95 range.
Street expects PFE's revenue and EPS for the fourth quarter (ending December 2024) to increase 22.1% and 362.8% year-over-year to $17.40 billion and $0.46, respectively. Furthermore, the company topped the consensus EPS estimates in all four trailing quarters.
PFE's stock has surged 3.4% over the past six months to close the last trading session at $28.09.
PFE's bright prospects are reflected in its POWR Ratings. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Growth. PFE also has a B grade for Value. PFE is ranked #32 among 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry.
<a href="https://stocknews.com/stock/PFE/">Click here</a> to access PFE's ratings for Quality, Momentum, Stability, and Sentiment.
Enterprise Products Partners L.P. (<a href="https://stocknews.com/stock/EPD/">EPD</a>)
EPD offers midstream energy services to producers and consumers of natural gas, natural gas liquids, crude oil, petrochemicals, and refined products. The company operates through four segments: NGL Pipelines &amp; Services; Crude Oil Pipelines &amp; Services; Natural Gas Pipelines &amp; Services; and Petrochemical &amp; Refined Products Services.
On October 29, EPD completed the second phase of its Texas Western Products system. Located in Grand County, Utah, the facility is a refined products truck terminal serving the Grand Junction, Colorado, and Moab, Utah areas. The facility has a storage capacity of 400,000 barrels for gasoline and diesel and can load trucks at a rate of up to 20,000 bpd.
On October 28, EPD completed the acquisition of Piñon Midstream, LLC. EPD purchased Piñon Midstream for $950 million in cash consideration as part of a debt-free transaction. The assets acquired under the transaction, including natural gas gathering and treating services, expanded EPD's footprint in the eastern flank of the prolific Delaware Basin of Texas and New Mexico.
Also, on October 2, EPD's Board of Directors declared a quarterly cash distribution to be paid to common unitholders for the third quarter of 2024 of $0.525 per unit. The distribution represents a 5% increase over the distribution declared last year. The distribution will be paid on November 14, 2024, to common unitholders of record as of the close of business on October 31, 2024.
EPD's annual distribution of $2.10 translates to a yield of 7.29% at the current unit price. Its four-year average dividend yield is 7.53%. Also, the company's dividend payouts have increased at a CAGR of 4.9% over the past three years. EPD has raised its dividend for 26 consecutive years.
During the third quarter of 2024, which ended September 30, 2024, EPD's total revenues increased 14.8% from the prior year period to $13.78 billion. Its operating income grew 5% from the year-ago value to $1.78 billion. The company's net income attributable to common unitholders amounted to $1.42 billion or $0.65 per unit, up 7.5% and 8.3% year-over-year, respectively.
In addition, the company's adjusted EBITDA rose 4.9% from the year-ago value to $2.44 billion.
Street expects EPD's EPS for the first quarter (ending March 2025) to increase 4.5% year-over-year to $0.70, and its revenue for the same quarter is expected to grow marginally year-over-year to $14.85 billion. Also, the company has surpassed the consensus EPS estimates in three of the trailing four quarters.
EPD's stock has gained 3.9% over the past six months and 11% over the past year to close the last trading session at $28.82.
EPD's POWR Ratings reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has a B grade for Value, Momentum, and Stability. Within the A-rated <a href="https://stocknews.com/category/oil-gas-mlps/">MLPs – Oil &amp; Gas</a> industry, EPD is ranked #5 among 23 stocks.
<a href="https://stocknews.com/stock/EPD/">Click here</a> to access additional EPD ratings for Sentiment, Growth, and Quality.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>
&nbsp;

<hr />
VZ shares were unchanged in after-hours trading Monday. Year-to-date, VZ has gained 16.17%, versus a 21.01% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/vz-pfe-epd-3-high-yield-dividend-stocks-to-buy-for-steady-passive-income/>3 High-Yield Dividend Stocks to Buy for Steady Passive Income</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 High-Yield Dividend Stocks to Buy for Steady Passive Income

Data Underwhelms - Intellia's Cash, Data And Competition Are A Challenging Story

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has given ...

Pfizer's Ponsegromab: A Promising Yet Uncertain Opportunity Influencing Hold Rating

As one of the world's top pharmaceutical firms, Pfizer ($PFE) is liable to see significant movement in its share price based on key fundamental dat...

Profit from Pfizer's (PFE) Post-Earnings Lull with a Short Iron Condor

Analyst Tewari holds a meeting with management in Seattle, WA on November 5 hosted by Jefferies. Published first on TheFly – the ultimate source fo...

Pfizer management to meet with Jefferies

ALNY

BNTX

GILD

IONS

NTLA

REGN

VRTX

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

MRNA

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Screenshot 2024-02-24 at 12.03.42 AM

ABBV

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

Pfizer's TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial

Starboard Value Issues Letter to Pfizer's Board of Directors

U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

Tim Buckley Elected to Pfizer's Board of Directors

ViiV Healthcare Shows More Than 99% Effectiveness in Real-World Studies for Apretude (Cabotegravir Long-Acting), the Only Approved Long-Acting HIV PrEP, in Data Presented at IDWeek 2024

Starboard Value Issues Presentation Delivered at 13D Monitor's 2024 Active-Passive Investor Summit

U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease

Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

KVUE

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Pfizer

매도 수량

Pfizer (NYSE:PFE) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌